Drug Profile
Research programme: obesity and type 2 diabetes mellitus therapeutics - Prosidion
Alternative Names: PSN 842Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Prosidion
- Class
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in United Kingdom (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in United Kingdom (PO)
- 21 Dec 2011 AstraZeneca is granted an exclusive option to acquire PSN 842 from Prosidion